首页|糖基化CD59在妊娠期糖尿病精准诊断中的研究进展

糖基化CD59在妊娠期糖尿病精准诊断中的研究进展

扫码查看
近年来,妊娠期糖尿病(GDM)患病率显著升高,引发产妇及其子代多种不良结局,而早期诊断和良好控制血糖可显著改善妊娠结局.目前,GDM诊断主要依据口服葡萄糖耐量试验(OGTT),但临床应用时存在诸多不足.新型生物学标志物糖基化CD59是一种补体调节蛋白的糖基化产物,可在体液中稳定存在,与血糖水平呈线性相关,具有测试简便、可重复性佳等优点,且已开发出可稳定使用的试剂盒,在GDM的早期诊断、标准诊断和妊娠结局预测等方面均显示出良好的价值.
Research progress of glycosylated CD59 in the precise diagnosis of gestational diabetes mellitus
In recent years,the prevalence of gestational diabetes mellitus(GDM)has signifi-cantly increased,leading to various adverse outcomes for mothers and their offspring.Early diagnosis and good blood glucose control can significantly improve pregnancy outcomes.Currently,the diagno-sis of GDM mainly relies on the oral glucose tolerance test(OGTT),but there are many limitations in clinical application.The new biological marker glycosylated CD59 is a glycosylation product of com-plement regulatory proteins that can stably exist in body fluids and is linearly related to blood glucose levels,which has the advantages of simple testing and good reproducibility,and has been developed into a stable reagent kit.It has shown good value in the early diagnosis,standard diagnosis,and pre-diction of pregnancy outcomes of GDM.

gestational diabetes mellitusglycosylated CD59precise diagnosispregnancy outcomesbiomarkerblood glucose

王婉莹、陆小凡、徐冲、张瑛、邹会玲、孙宇

展开 >

徐州医科大学研究生院,江苏徐州,221004

徐州医科大学附属宿迁医院内分泌科,江苏宿迁,223800

妊娠期糖尿病 糖基化CD59 精准诊断 妊娠结局 生物标志物 血糖

江苏省卫生健康委科研项目面上项目江苏省宿迁市重点研发项目

M2020094S202211

2024

实用临床医药杂志
扬州大学,中国高校科技期刊研究会

实用临床医药杂志

CSTPCD
影响因子:1.543
ISSN:1672-2353
年,卷(期):2024.28(4)
  • 39